{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:08:57Z","timestamp":1774534137616,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,9,14]],"date-time":"2007-09-14T00:00:00Z","timestamp":1189728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with either relapsed or refractory T\u2010cell acute lymphocytic leukemia (T\u2010ALL) are candidates for allogeneic hematopoietic stem cell transplantation (allo\u2010HSCT). Achieving complete remission (CR) in these patients is difficult but crucial for the success of allo\u2010HSCT. In this study, we examined 6 relapsed or refractory T\u2010ALL patients. In the patient group, 4 were male and 2 were female, with ages ranging from 15 to 57 years (median = 29 years). All 6 patients presented with the nonmature T\u2010ALL phenotype. Cytogenetically, only one had an i(7q) anomaly, whereas the remaining 5 cases had normal karyotypes. One of these patients had the MLL\/AF9 fusion transcript, as shown by molecular study. After initial remission\u2010induction therapy, two patients achieved CR, one showed a partial remission, and all relapsed soon. The other 3 cases failed the therapy. The CAG regimen (cytosine arabinoside 10 mg\/m<jats:sup>2<\/jats:sup> subcutaneously every 12 hr, day 1\u201314; aclarubicin 5\u20137 mg\/m<jats:sup>2<\/jats:sup> intravenously daily, day 1\u20138; and concurrent use of G\u2010CSF 200 \u03bcg\/m<jats:sup>2<\/jats:sup>\/day subcutaneously) was devised originally for the treatment of relapsed acute myelogenous leukemia. After CAG therapy, all the T\u2010ALL patients in our study achieved CR, indicating that the CAG regimen is beneficial to the treatment of relapsed or refractory T\u2010ALL. The efficacy of CR\u2010induction in T\u2010ALL patients and the adverse effects of the CAG regimen need to be further studied. Am. J. Hematol., 2008. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21066","type":"journal-article","created":{"date-parts":[[2007,9,14]],"date-time":"2007-09-14T16:16:36Z","timestamp":1189786596000},"page":"167-170","source":"Crossref","is-referenced-by-count":13,"title":["CAG regimen enables relapsed or refractory T\u2010cell acute lymphocytic leukemia patients to achieve complete remission: A report of six cases"],"prefix":"10.1002","volume":"83","author":[{"given":"Sheng\u2010Li","family":"Xue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De\u2010Pei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai\u2010Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao\u2010Wen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,9,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400861"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1203::AID-CNCR15>3.0.CO;2-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2155::AID-CNCR2820720715>3.0.CO;2-V"},{"key":"e_1_2_1_6_2","first-page":"10","article-title":"Concurrent use of granulocyte colony\u2010stimulating factor with low\u2010dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: A pilot study","volume":"9","author":"Yamada K","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2214"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808273390907"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.116"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1031"},{"key":"e_1_2_1_11_2","first-page":"165","article-title":"Comparison of low\u2010dose cytosine arabinoside and aclarubicin in combination with granulocyte colony\u2010stimulating factor to intermediate\u2010dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia","volume":"36","author":"Saito K","year":"1995","journal-title":"Rinsho Ketsueki"},{"key":"e_1_2_1_12_2","first-page":"238","article-title":"Low\u2010dose cytarabine and aclarubicin in combination with granulocyte colony\u2010stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation","volume":"71","author":"Saito K","year":"2000","journal-title":"Int J Hematol"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.A10424"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(98)00041-1"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053552"},{"key":"e_1_2_1_16_2","first-page":"2638","article-title":"A new technic of analysis of the human karyotype","volume":"272","author":"Dutrillaux B","year":"1971","journal-title":"C R Acad Sci Hebd Seances Acad Sci D"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.2.574"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.1.163.163"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V32.4.507.507"},{"key":"e_1_2_1_20_2","volume-title":"Handbook for Reporting Results of Cancer Treatment","author":"World Health Organization","year":"1979"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:38:37Z","timestamp":1700066317000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,14]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1002\/ajh.21066"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21066","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,14]]}}}